Oncotelic Therapeutics (OTCQB: OTLC) announced the launch of its artificial intelligence-powered good manufacturing practices (GMP) manufacturing services platform at the 2026 BIO International Convention in San Diego. The platform integrates the company’s proprietary PDAOAI technology with advanced robotics provided through a collaboration with TechForce Robotics, aiming to support pharmaceutical, biotechnology and advanced therapeutics companies in modernizing manufacturing operations.
According to the company, the platform is designed to handle electronic batch records, manufacturing documentation, GMP workflow digitization, quality and compliance functions, and process monitoring. By leveraging AI-driven workflows and intelligent automation, Oncotelic seeks to address the growing need for efficient and compliant manufacturing in the life sciences sector.
In addition to the platform launch, Oncotelic will showcase progress with its Deciparticle nanomedicine platform, including SAPU003, a clinical-stage intravenous everolimus program currently being evaluated in a Phase 1b study. The company’s CEO, Dr. Vuong Trieu, has filed over 500 patent applications and holds 75 issued U.S. patents, underscoring the innovative foundation of the company’s pipeline.
Oncotelic’s PDAOAI platform underpins the new GMP manufacturing services and is also used for drug discovery and lab automation. The company owns 45% of GMP Bio, a joint venture that advances complementary drug candidates in oncology and rare disease therapeutics. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, Oncotelic continues to develop the platform in collaboration with TechForce Robotics.
The implications of this announcement are significant for the pharmaceutical industry, as AI-powered manufacturing can reduce costs, improve quality control, and accelerate time-to-market for new therapies. The partnership with TechForce Robotics brings purpose-built automation solutions to GMP environments, potentially setting a new standard for manufacturing efficiency. For Oncotelic, the platform represents a strategic expansion beyond drug development into service-based offerings, creating new revenue streams and strengthening its position in the biotech ecosystem.
TechForce Robotics is the operating brand of Nightfood Holdings, Inc., and designs robotics and automation solutions for pharmaceutical manufacturing and other applications. The collaboration with Oncotelic aims to deploy advanced robotics integrated with AI to streamline production processes.
Investors and industry observers can find more information about Oncotelic in the company’s newsroom at https://ibn.fm/OTLC.
